IDENTIFICATION OF TRICYCLIC ANALOGS RELATED TO ELLAGIC ACID AS POTENT SELECTIVE TYROSINE PROTEIN-KINASE INHIBITORS

被引:39
|
作者
DOW, RL [1 ]
CHOU, TT [1 ]
BECHLE, BM [1 ]
GODDARD, C [1 ]
LARSON, ER [1 ]
机构
[1] ONCOGENE SCI INC,MANHASSET,NY 11030
关键词
D O I
10.1021/jm00040a015
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The plant-derived natural product ellagic acid (1) has recently been identified as a potent, though nonselective, inhibitor of the tyrosine-specific protein kinase pp60(src). This report details efforts directed toward the identification of tricyclic structures related to ellagic acid, with enhanced specificity for inhibition of pp60(src) over other protein kinases. Phenanthridinone and carbazole core structures were selected for investigation, since N-functionalization allows for the synthesis of numerous analogs which can be utilized to probe enzyme-inhibitor interactions. These ring systems were prepared via a general sequence of biaryl bond formation followed by cyclization to form the desired tricyclic ring systems. N-Alkylation, -acylation, or -sulfonylation and deprotection with boron tribromide afford the target tetraphenolic phenanthridinones 5 and carbazoles 9. Several analogs from both of these series have potencies comparable to that of 1 and exhibit substantially enhanced selectivities for inhibition of pp60(src) relative to protein kinase A (PKA), a serine/threonine protein kinase. Carbazole-based analogs 9j,m,p are submicromolar inhibitors of pp60(src), with potency for the target tyrosine kinase comparable to that of ellagic acid (1), however with 2 orders of magnitude greater selectivity versus that for PKA. As seen for ellagic acid, members of the phenanthridinone-based series (e.g., 5a) exhibited inhibition of pp60(src) in a manner which is partial mixed noncompetitive with respect to ATP, while analogs in the carbazole series (e.g., 9a) inhibit pp60(src) in an ATP competitive manner.
引用
收藏
页码:2224 / 2231
页数:8
相关论文
共 50 条
  • [41] Design and discovery of new selective and potent VEGF receptor 2 tyrosine kinase inhibitors
    Hou, Fei
    Yao, Yuhong
    Wei, Yujiao
    Wang, Yubo
    Cao, Yangzi
    Liu, Xinqiang
    Zheng, Liting
    Zhang, Qingqing
    Jiao, Yue
    Chen, Yukun
    Meng, Yue
    Sun, Yue
    Wu, Yanjie
    Wang, Jiefu
    Wang, Junfeng
    Wu, Zhou
    Zhang, Kun
    Wei, Mingming
    Yang, Guang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 91
  • [42] Tyrosine kinase inhibitors are potent and selective inhibitors of UGT1A1: Tools for UGT phenotyping
    Kalyanaraman, Nataraj
    Li, Chun
    Surapaneni, Sekhar S.
    Kumar, Gondi N.
    DRUG METABOLISM REVIEWS, 2006, 38 : 43 - 43
  • [43] Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834
    Young, Wendy B.
    Barbosa, James
    Blomgren, Peter
    Bremer, Meire C.
    Crawford, James J.
    Dambach, Donna
    Gallion, Steve
    Hymowitz, Sarah G.
    Kropf, Jeffrey E.
    Lee, Seung H.
    Liu, Lichuan
    Lubach, Joseph W.
    Macaluso, Jen
    Maciejewski, Pat
    Maurer, Brigitte
    Mitchell, Scott A.
    Ortwine, Daniel F.
    Di Paolo, Julie
    Reif, Karin
    Scheerens, Heleen
    Schmitt, Aaron
    Sowell, C. Gregory
    Wang, Xiaojing
    Wong, Harvey
    Xiong, Jin-Ming
    Xu, Jianjun
    Zhao, Zhongdong
    Currie, Kevin S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (06) : 1333 - 1337
  • [44] The use of a pharmacophore model for the design of potent and selective EGFR tyrosine kinase inhibitors.
    Traxler, P
    Bold, G
    Buchdunger, E
    Lang, M
    Mett, H
    Furet, P
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U890 - U891
  • [45] INDOLOCARBAZOLES AND BISINDOLYLMALEIMIDES AS POTENT AND SELECTIVE INHIBITORS OF PROTEIN-KINASE-C
    HARTENSTEIN, J
    BARTH, H
    KLEINSCHROTH, J
    BETCHE, HJ
    RECK, R
    RUDOLPH, C
    SCHACHTELE, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 74 - MEDI
  • [46] Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy
    Miles, D.
    Chen, Y.
    Paprcka, S. L.
    Foley, C. N.
    Grange, R.
    Leleti, M. R.
    Zhao, X.
    Jin, L.
    Young, S. W.
    Walters, M. J.
    Powers, J. P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S38 - S39
  • [47] Novel potent and selective inhibitors of protein kinase CK2
    Prudent, R.
    Moucadel, V
    Laudet, B.
    Cochet, C.
    BULLETIN DU CANCER, 2008, 95 : S66 - S66
  • [48] Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs
    Haddach, Mustapha
    Pierre, Fabrice
    Regan, Collin F.
    Borsan, Cosmin
    Michaux, Jerome
    Stefan, Eric
    Kerdoncuff, Pauline
    Schwaebe, Michael K.
    Chua, Peter C.
    Siddiqui-Jain, Adam
    Macalino, Diwata
    Drygin, Denis
    O'Brien, Sean E.
    Rice, William G.
    Ryckman, David M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 45 - 48
  • [49] [(ALKYLAMINO)METHYL]ACRYLOPHENONES - POTENT AND SELECTIVE INHIBITORS OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR PROTEIN-TYROSINE KINASE
    TRAXLER, P
    TRINKS, U
    BUCHDUNGER, E
    METT, H
    MEYER, T
    MULLER, M
    REGENASS, U
    ROSEL, J
    LYDON, N
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (13) : 2441 - 2448
  • [50] Exploration of biguanido–oxovanadium complexes as potent and selective inhibitors of protein tyrosine phosphatases
    Liping Lu
    Xiaoli Gao
    Miaoli Zhu
    Sulian Wang
    Qiong Wu
    Shu Xing
    Xueqi Fu
    Zhiwei Liu
    Maolin Guo
    BioMetals, 2012, 25 : 599 - 610